Daily non-political popular news in brief.

Researchers identify new drug targets for cancer

Solving a 100-year-old genetic puzzle, researchers at the UCSD School of Medicine have determined that the same genetic mechanism that drives tumor growth can also act as a tumor suppressor. Their findings could lead to new drug targets for cancer therapies.

Read more »

Keywords: researchers, identify, drug, targets, cancer, researcher, target

« Previous | Next »

Similar news on "Researchers identify new drug targets for cancer":

1. Jefferson scientists identify protein key to breast cancer spread, potential new drug target
   04-09-2007 · EurekAlert!
   Researchers at the Kimmel Cancer Center at Jefferson have identified a protein that they say is key to helping a quarter of all breast cancers spread. The finding, reported online the week of April 9, 2007, in the journal Proceedings of the National Academy of Sciences, could be a potential target for new drugs aimed at stopping or slowing the growth and progression of breast cancer.
   Similar news · Read more »
   
2. Animal study identifies promising new target for brain tumor therapy
   05-08-2007 · EurekAlert!
   A drug that targets the body's immune cells may be effective in treating malignant brain tumors, according to a new study led by researchers from Duke's Preston Robert Tisch Brain Tumor Center. In animal models, the drug re-engaged the body's cancer-damaged immune system.
   Similar news · Read more »
   
3. MIT model could predict cells' response to drugs
   07-30-2007 · EurekAlert!
   MIT researchers have developed a model that could predict how cells will respond to targeted drug therapies. Models based on this approach could help doctors make better treatment choices and drug developers identify the ideal compound. In addition, the model could help test the effectiveness of drugs for a wide range of diseases, including cancer, arthirtis, and immune system disorders.
   Similar news · Read more »
   
4. Kidney cancer drug attacks a major type of acute myeloid leukemia
   01-29-2008 · EurekAlert!
   A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with acute myeloid leukemia, the most common and lethal form of adult leukemia, researchers at The University of Texas M. D. Anderson Cancer Center report in the Jan. 29 edition of the Journal of the National Cancer Institute.
   Similar news · Read more »
   
5. A new target for the treatment of breast cancer
   01-11-2007 · EurekAlert!
   The active ingredient in a drug currently being tested to treat rheumatoid arthritis might also one day serve as an effective means of treating one of the deadliest forms of breast cancer. Berkeley Lab researchers have demonstrated that inhibiting the activity of the protease enzyme known as TACE can deprive tumor cells of a key factor needed for their proliferation. TACE is strongly present in a form of breast cancer which responds poorly to current therapies.
   Similar news · Read more »
   
6. Support for chromosomal theory of cancer found in cancers' development of drug resistance
   06-27-2007 · EurekAlert!
   Most cancer researchers are convinced that cancer results from a handful of genetic mutations that kick a cell into uncontrolled growth. UC Berkeley genetics researcher Peter Duesberg disagrees, and finds support for his "chromosomal" theory of cancer in the development of drug resistance by many cancers. While his theory implies their is no magic bullet against cancer, it does provide ways to detect cancer at an early stage.
   Similar news · Read more »
   
7. First report that apoptotic and anti-angiogenic therapies work better together than alone
   11-10-2006 · EurekAlert!
   American researchers have found that giving a combination of imantanib and a drug that induces cell death was better at inhibiting the growth of Ewing's sarcoma in mice than either therapy on its own, according to research presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague on Friday.
   Similar news · Read more »
   
8. M. D. Anderson reports first drug activity in T315I-Positive CML, ALL and JAK-2-Positive MPD
   12-11-2006 · EurekAlert!
   Researchers at the University of Texas M. D. Anderson Cancer Center reported today that MK-0457 (VX-680), a novel multi-kinase inhibitor, is clinically active against multiple target mutations in two types of leukemia and myeloproliferative disorders, and produces few side effects for patients.
   Similar news · Read more »
   
9. Investigational cancer drug targets critical proteins
   04-14-2007 · EurekAlert!
   A drug under study to treat various cancers selectively kills cancer cells because of its affinity for a modified version of a critical heat shock protein they contain, researchers have found.
   Similar news · Read more »
   
10. Patients respond well to first study to test higher doses of an anti-cancer drug
    11-10-2006 · EurekAlert!
    Researchers in the UK and the United States have found that a drug composed of an antibody carrying a highly toxic anti-cancer agent is well tolerated by patients at much higher doses than have been used before, according to research presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague on Friday.
    Similar news · Read more »